Murty Bosukonda

Director/Board Member at Thrasos, Inc.

Health Technology

Profile

Murty Bosukonda is the founder of Thrasos Therapeutics, Inc. which was founded in 2003.
Currently, he holds the position of Executive Director at Thrasos, Inc.

Murty Bosukonda active positions

Companies	Position	Start
Thrasos, Inc. Thrasos, Inc. Pharmaceuticals: MajorHealth Technology Thrasos, Inc. discovers and develops drugs. The company develops protein mimetic compounds for Kidney and Heart disease. Thrasos is headquartered in Hopkinton, MA	Director/Board Member	-

All active positions of Murty Bosukonda

Former positions of Murty Bosukonda

Companies	Position	End
Thrasos Therapeutics, Inc. Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada.	Founder	-

See the detail of Murty Bosukonda's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Murty Bosukonda's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Thrasos, Inc. Thrasos, Inc. Pharmaceuticals: MajorHealth Technology Thrasos, Inc. discovers and develops drugs. The company develops protein mimetic compounds for Kidney and Heart disease. Thrasos is headquartered in Hopkinton, MA	Health Technology
Thrasos Therapeutics, Inc. Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada.	Health Technology